• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Tumor Treating Fields Mesothelioma

Tumor treating mesothelioma caused by fields is a new kind of therapy that uses alternating electric fields to limit cancer growth. It is used in combination with chemotherapy to treat the pleural cancer.

Following the success of the STELLAR study The FDA approved TTFields together with pemetrexed-cisplatin. the year 2019 saw the FDA approved TTFields. Patients can consult their physician for this treatment.

Disrupting Cell Division

TTFields use alternation of electrical fields to destroy cancer cell proteins and thrifty-dinosaur-fmrsv4.mystrikingly.com post to a company blog block their cells from growing. This can stop mesothelioma from expanding or growing in other organs. The TTFields help to trigger the release of proteins that kill cancerous cells and help the immune system in fighting mesothelioma tumours.

During treatment patients wear a small device with insulated pads that are bonded to the skin. The device delivers low-intensity electric current, and patients are able to regulate the amount of treatment they receive. A mesothelioma therapy session lasts approximately 30 minutes. Patients can receive TTFields treatment multiple times a day.

A TTFields research study published in 2021 showed that the intensity of electrical fields of 100 to 300 Kilohertz could stop cell division in cancer cells and cause them to die. The study examined different kinds of cancer cells, and discovered that electrical fields killed all of them, regardless of cellular structure.

The study's authors recommended mixing TTFields with chemotherapy for mesothelioma. FDA approved Novocure's TTFields NovoTTF 100L in the year 2019 for the treatment of non-resectable mesothelioma pleural. It is now available through mesothelioma specialists in certified medical centers in the U.S. including the West Cancer Center, http://www.rheinische-gleisbautechnik.de/ Memphis. The NovoTTF-100L device, which is now called Optune Lua, has been used to treat mesothelioma in combination with chemotherapy based on platinum. Mesothelioma patients have reported a longer survival when the TTFields therapy is paired with chemotherapy.

Another study published in "Lung Cancer", reported that TTFields therapy is effective when combined with chemotherapy. In the study, researchers discovered that combining chemotherapy and TTFields reduced the number of malignant mesothelioma cells in animal models by more than 80%. The study also showed that the combination of these two treatments increased the production of proteins that kill mesothelioma cells and reduce the amount of cancerous DNA found in the body.

Despite being an emerging treatment, many mesothelioma specialists don't offer TTFields to treat pleural mesothelioma. Patients may still be able to access this treatment through clinical trials, or at Novocure-certified mesothelioma clinics.

Stalling Tumor Development

Mesothelioma forms when mesothelial cells mutate and outlive their normal lifespan, resulting in an overabundance of diseased cells that expand and multiply in the body. treatment for stage 1 mesothelioma for tumors prevents mesothelial cell duplication and prevent mesothelioma growing and spreading.

The TTFields device, which is worn on the chest as a vest produces a series electrical fields that can disrupt protein and kill cancer cells and slow the growth of tumors. The device comes with an insulated pad that sticks to the skin and can be applied at home by patients or by health professionals who have been trained by Novocure.

Doctors recommend mixing TTFields treatment with chemotherapy for the most effective results. The combination boosts production of proteins that kill cancerous cells, and reduces cancer cells' ability to repair DNA damage from chemotherapy drugs. This makes chemotherapy drugs perform more effectively and improves survival in mesothelioma patients.

In the STELLAR trial conducted in 2017 TTFields therapy combined with chemotherapy significantly improved survival for mesothelioma patients. In the year 2019, the FDA approved the NovoTTF 100L System, now marketed under Optune Lua for use with pemetrexed, Cisplatin, or carboplatin, as a first-line treatment of malignant pleural mesothelioma treatment and prognosis melanoma that is not resectable.

Researchers have found that the TTFields treatment can fight mesothelioma by stopping cell division. The TTFields therapy causes cancer cells to break up in a mitosis process. The cellular debris is absorbed by surrounding tissues and inhibits the growth new tissue. Mitosis stops mesothelioma tumor cells from repairing damaged genetic material and makes them more susceptible to radiation therapy.

The TTFields treatment is also able to reduce the flow of blood to tumors by reducing vascular endothelial growth factor, or VEGF, and by increasing hypoxia-inducible factor-1 beta, or HIF-1a, which is linked with cancer cell angiogenesis.

If you've been diagnosed with mesothelioma, talk to your physician about whether TTFields is right for you. Novocure and a number of mesothelioma specialists are conducting clinical trials to evaluate the efficacy of TTFields. To find out more about how mesothelioma-TTFields might benefit your treatment plan, contact a Novocure-certified specialist at one of the more than 1,300 U.S. treatment centers.

Killing Tumor Cells

Tumor-treating fields for treating tumors (TTFields), which send electrical waves throughout the body. They disrupt cell division and eliminate cancer cells. TTFields target cancerous cells while protecting healthy cells. The electric fields also decrease DNA repair and boost the immune system of cells, making it harder for cancerous cells to survive. TTF is non-invasive and causes only mild negative effects.

Scientists think TTFields function by disrupting mitosis, which is the process through which the cell divides into two identical new cells. Normal cells have rules in place to limit the rate of mitosis, but malignant cancerous cells override this control and grow rapidly. TTFields interfere with this process by blocking signals that regulate the growth of mesothelioma tumor cells. In the STELLAR study, TTFields when combined with chemotherapy significantly increased survival rates in mesothelioma patients. Mesothelioma survivors who received TTFields together with maintenance cycles of chemotherapy lasted six months longer on average than those who just received chemotherapy.

In a different study, it was discovered that TTFields could boost the effectiveness of certain chemotherapy drugs known as platinum-based treatments. These platinum-based therapies kill mesothelioma by targeting mitochondria. This is where the energy for cancerous cells originates. When TTFields is used in conjunction with these chemotherapies the combination can result in higher levels DNA damage and faster cancer cell death.

TTFields may also boost the effects of radiation therapy in some instances. Scientists have discovered that the combination of TTFields and radiation therapy may produce a "synergistic" effect. This means that the combination treatment enhances the sensitivity of tumor cells to radiation.

Currently, TTFields are available at some mesothelioma centers. However, a mesothelioma expert can determine whether you may be suitable for this treatment. If you are eligible an attorney for mesothelioma can help you access treatment that incorporates TTFields along with chemotherapy. A mesothelioma lawyer can assist veterans get VA-covered treatment.

Side Effects

The TT fields therapy disrupts cancer cells by generating an electrical field that hinders the cell's ability to divide. This can slow down the growth of a tumor and prevent it from spreading to other parts of the body. The TT Fields device is not invasive. It does not cause pain or damage to the surrounding tissue. This is a different approach than traditional chemotherapy which involves radiation and injections into the intravenous vein, which can cause serious side effects.

In the study in which patients received a combination of TT fields and temozolomide experienced survival improvements comparable to those of people treated with chemo on their own. Doctors attributing the improved survival to TT fields their ability to enhance the effectiveness of chemo and lessen the risk of the adverse effects.

Mesothelioma cancer cells can mutate and multiply in uncontrolled ways, causing cancerous cells to invade your organs. Mesothelioma treatment such as TT fields prevent mesothelioma from reproducing and hindering the body's normal functions by stopping cell division.

In a mesothelioma research study, patients who received TT-fields together with chemotherapy had an average survival rate (18.2 months). Patients who received TT fields without chemotherapy had a median survival of 12.1 months.

Tumor treating fields can be applied to the pleura, or the thin lining that covers your lungs, whether on your abdomen or chest wall. The device is small and can be worn all day long even during sleep time. Patients can continue their daily life and work even while they undergo treatment for mesothelioma.

TT fields can be added with conventional chemotherapy or immunotherapy, as well as other mesothelioma treatment. Mesothelioma patients who are interested in TT fields should discuss this possibility with their mesothelioma specialist who can provide the eligibility requirements and anticipated benefits for the patient's particular case.